Here’s the intro to their piece
Psychedelics are slowly gaining social acceptance as a valuable therapeutic drug to treat mental health illnesses, but the heavily regulated industry still faces many roadblocks in Canada.
Once vilified, some psychedelics are now classified by the U.S. Food and Drug Administration as a potential “breakthrough therapy” for major depressive disorder. Psychedelic drugs, including psilocybin, LSD and ketamine, are now used to help people with post-traumatic stress disorder, anxiety or depression who are resistant to conventional treatments.
Lawyers at companies that develop psychedelic therapies call for more relaxed regulations to make their therapies more widely available to medical professionals.
Read article at